via twitter.com
Computational modelling has been used to create dual-action compounds with exciting potential as new antibiotics.
The proof of principle experiment raises the possibility of new antibiotics that can target harmful bacteria on two fronts and consequently are less likely to be overcome by resistant strains.
The University of Leeds/John Innes Centre collaboration modelled potential new drugs based on the activity of thiophene compounds. These had previously shown promise as antibiotics before toxicity issues prevented them from going forward to human clinical trials.
Observing the activity of the thiophenes, the team computationally modelled new antibiotic candidates and then synthesised and tested them on pathogenic bacteria Escherichia coli (E. coli).
They found a series of biphenyl-based compounds inhibited the activity of the harmful bacteria by targeting two enzymes, DNA gyrase, and DNA topoisomerase IV, both of which are essential to bacterial survival.
“These novel compounds represent the start of a programme that could lead to a new series of antibiotics,” said Professor Tony Maxwell, of the John Innes Centre, and one of the authors of the study.
“The current programme represents a proof of principle, and this initial success suggests we will be able to discover even better antibiotic candidates going forward.” added first author of the study, University of Leeds researcher Dr Kyle Orritt. 23e o9
The researchers have already discussed the implications of the work with pharmaceutical companies, raising the possibility of a new source of antibiotics.
This work follows the discovery of a new possibility of exploiting the established antibacterial target DNA gyrase which offers a new medicinal chemistry strategy.
New antibiotics are urgently needed owing to the evolution of bacteria which are resistant to existing treatments. This problem of antimicrobial resistance (AMR) poses an enormous threat to human health due to an increase in the number of untreatable bacterial infections.
By 2050 it is predicted that AMR will be responsible for 10 million global deaths annually, more deaths than cancer and costing the world economy $100 trillion.
Original Article: Could cyber designs deliver potent dual-action antibiotics?
More from: University of Leeds | John Innes Centre
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Dual-action antibiotics
- Could cyber designs deliver potent dual-action antibiotics?
Computational modeling has been used to create dual-action compounds with exciting potential as new antibiotics. The proof of principle experiment raises the possibility of new antibiotics that can ...
- Daily Biotech/Pharma Pulse: July 7
VDCs created by the company are a new class of drugs and have a dual mechanism of action. They promote the ... in hospitalized patients treated with antibiotics and immunocompromised patients ...
- Resistant 'Superbugs' Create Need for Novel Antibiotics
Its spread into the population at large has required a dual classification for ... has created an urgent need for antibiotics with unique mechanisms of action. Most of the current available ...
- MCRA Assists BONESUPPORT AB with the First Ever Combination Product DeNovo Decision Granted by the U.S. FDA
an implantable device/drug combination bone void filler that provides a one-stage approach for the management of bone infection with its unique dual mode of action that delivers proven bone ...
- Answers and Critiques to CIA 1
In these children dual DT antigen is preferred ... contaminated and it is better to treat the wound with broad-spectrum antibiotics even prophylactically. All injures do not require antibiotic ...
Go deeper with Google Headlines on:
Dual-action antibiotics
Go deeper with Bing News on:
Thiophene compounds
- Could cyber designs deliver potent dual-action antibiotics?
Computational modeling has been used to create dual-action compounds with exciting potential as new antibiotics. The proof of principle experiment raises the possibility of new antibiotics that can ...
- SGLT2 Inhibitors: FDA Approval of Canagliflozin for Type 2 Diabetes Therapy
The pharmacokinetics of this compound are similar in study subjects with diabetes and in those without. Age, gender, body weight, race, administration with food, or mild renal impairment do not ...
- Antivirals: Current State of the Art
Most of the antiviral agents that have been approved, and are currently used in the treatment of virus infections, are targeted at HIV, HBV, herpes simplex virus (HSV), varicella-zoster virus (VZV ...
- Alfa Chemistry Launches Thiophenes as Heterocyclic Organic Compounds for Academic Research and Industrial Manufacturing
Overall, thiophene moiety hikes a great deal of interest ... More recently, a large number of heterocyclic compounds have been introduced to support the academic and commercial search for a ...
- Alfa Chemistry Launches Thiophenes as Heterocyclic Organic Compounds for Academic Research and Industrial Manufacturing
Extensively existing in nature, heterocyclic organic compounds are of paramount importance in medicinal chemistry, the discovery of novel drugs in particular. Fully aware of the market demand for such ...